## PATENT COOPERATION TREATY

DOCKETED

NO

NOV 1 2 2003

### From the INTERNATIONAL SEARCHING AUTHORITY

To:
MCDONNELL BOEHNEN HULBERT
& BERGHOFF
Attn. Singer, Christopher P.
300 South Wacker Drive
Suite 3200
Chicago, IL 60606
UNITED STATES OF AMERICA

PCT BY: 1-6-04

NOTIFICATION OF TRANSMITTAL OF 2 - 6
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION


Suite 3200 Chicago, IL 60606 UNITED STATES OF AMERICA	(PCT Rule 44.1)				
	Date of mailing (day/month/year) 06/11/2003				
Applicant's or agent's file reference					
02-456-A	FOR FURTHER ACTION See paragraphs 1 and 4 below				
International application No.	International filing date				
PCT/US 03/20383	(day/month/year) 27/06/2003				
Applicant					
ELAN PHARMACEUTICALS, INC.					
1. X The applicant is hereby notified that the International Search	n Report has been established and is transmitted herewith.				
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim	ns of the International Application (see Rule 46):				
	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.				
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14.35	34, chemin des Colombettes 1211 Geneva 20, Switzerland				
For more detailed instructions, see the notes on the acco	mpanying sheet.				
2. The applicant is hereby notified that no International Search Article 17(2)(a) to that effect is transmitted herewith.					
3. With regard to the protest against payment of (an) addition	onal fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.					
no decision has been made yet on the protest; the app	no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.				
4. Further action(s): The applicant is reminded of the following:					
Shortly after <b>18 months</b> from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 <i>bis</i> .1 and 90 <i>bis</i> .3, respectively, before the completion of the technical preparations for international publication.					
Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).					
Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.					

Name and mailing address of the International Searching Authority

<u>@</u>)

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Authorized officer

Nicolas Michaleczek



In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

#### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

#### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
   "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:

  \*Claims 1 to 5 and 14 unchanged plaims 7 to 13 appealled new plaims 15 15 and 17 added to 2.
  - "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

#### It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

#### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

#### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

## PATENT COOPERATION TREATY







## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 02-456-A	FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, Item 5 below.				
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/US 03/20383	27/06/2003	27/06/2002			
Applicant  ELAN PHARMACEUTICALS, INC					
according to Article 18. A copy is being tra	_				
	international search was carried out on the bar less otherwise indicated under this item.	sis of the international application in the			
the international search w Authority (Rule 23.1(b)).	vas carried out on the basis of a translation of t	he international application furnished to this			
was carried out on the basis of th  contained in the internation  filed together with the internation	<ul> <li>b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: <ul> <li>contained in the international application in written form.</li> <li>filed together with the international application in computer readable form.</li> <li>furnished subsequently to this Authority in written form.</li> </ul> </li> </ul>				
the statement that the sul	o this Authority in computer readble form. osequently furnished written sequence listing d	loes not go beyond the disclosure in the			
	international application as filed has been furnished.  the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished				
4. With regard to the title,  X the text is approved as submitted by the applicant.  the text has been established by this Authority to read as follows:					
5. With regard to the <b>abstract</b> ,  X the text is approved as submitted by the applicant.  the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.					
6. The figure of the <b>drawings</b> to be pub  as suggested by the appl because the applicant fail because this figure better	icant.	None of the figures.			

#### INTERNATIONAL SEARCH REPORT

PCT/46 03/20383

## A. CLASSIFICATION OF SUBJECT MATTE IPC 7 A61K31/4174 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, BIOSIS

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to daim No.
P,X	WO 03 047576 A (VARGHESE JOHN ;ELAN PHARM INC (US)) 12 June 2003 (2003-06-12) the whole document	1-8,15, 16,19-22
A	THOMPSON S K ET AL: "Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-dased HIV-1 protease inhibitor containing a heterocyclic P1'-P2' amide bond isostere" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 37, no. 19, 16 September 1994 (1994-09-16), pages 3100-3107, XP002178684 the whole document	1-8,15, 16,19-22

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
Special categories of cited documents:  A document defining the general state of the art which is not considered to be of particular relevance  E earlier document but published on or after the international filing date  L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  O document referring to an oral disclosure, use, exhibition or other means  P document published prior to the international filing date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>		
Date of the actual completion of the international search  27 October 2003	Date of mailing of the international search report $06/11/2003$		
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer Ansaldo, M		

1

## INTERNATIONAL SEARCH REPORT

PCT/16 03/20383

DE DEL EVANT	
	Relevant to claim No.
WO 02 02505 A (ELAN PHARM INC) 10 January 2002 (2002-01-10) abstract	1-8,15, 16,19-22
WO 01 70672 A (ELAN PHARM INC) 27 September 2001 (2001-09-27) abstract	1-8,15, 16,19-22
WO 98 22430 A (THORSETT EUGENE D ;AUDIA JAMES E (US); JOHN VARGHESE (US); LATIMER) 28 May 1998 (1998-05-28) abstract	1-8,15, 16,19-22
	10 January 2002 (2002-01-10) abstract W0 01 70672 A (ELAN PHARM INC) 27 September 2001 (2001-09-27) abstract W0 98 22430 A (THORSETT EUGENE D ; AUDIA JAMES E (US); JOHN VARGHESE (US); LATIMER) 28 May 1998 (1998-05-28)

1

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9-14, 17-18

Present claims 9-14, 17 relate to a method defined by reference to a desirable characteristic or property, namely "for inhibiting beta-secretase activity", "for inhibiting cleavage...", "for inhibiting production of...".

The claims cover all methods having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT for only a very limited number of such methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to methods for treating or preventing Alzheimer's disease or to the diseases clearly mentioned in claim 5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims $1-7$ , $9-14$ , $16-20$ are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: 9-14, 17-18 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	•
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	t on Protest  The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 03/20383

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03047576	Α	12-06-2003	WO	03047576 A1	12-06-2003
WO 0202505	A	10-01-2002	AUUUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	7168601 A 7309401 A 7311301 A 7313701 A 0111980 A 0112000 A 2410651 A1 2410680 A1 2410972 A1 1447789 T 1443155 T 1299349 A2 1299352 A2 1353898 A2 20026199 A 0202505 A2 0202518 A2 0202518 A2 0202518 A2 0202512 A2 2002143177 A1 2003096864 A1 2002128255 A1 2002016320 A1	14-01-2002 14-01-2002 14-01-2002 14-01-2002 14-01-2002 06-05-2003 03-06-2003 10-01-2002 10-01-2002 08-10-2003 17-09-2003 09-04-2003 22-10-2003 22-10-2003 10-01-2002 10-01-2002 10-01-2002 10-01-2002 10-01-2002 22-05-2003 12-09-2002 07-02-2002
WO 0170672	Α	27-09-2001	AU CA EP WO US US	5295801 A 2401749 A1 1265849 A2 0170672 A2 2002022623 A1 2002019403 A1 2003013881 A1	03-10-2001 27-09-2001 18-12-2002 27-09-2001 21-02-2002 14-02-2002 16-01-2003
WO 9822430	A	28-05-1998	AU AU AU AU AU AU AU AU BRR CN CP EP UJP NOO NZ PL TR WO WO	739035 B2 5249898 A 729133 B2 5267798 A 9713351 A 9713404 A 1237960 A 1238760 A 0951464 A1 0946499 A1 0000492 A2 2001505204 T 2001505204 T 2001504498 T 992381 A 992463 A 334950 A 335280 A 334516 A1 9901128 T2 9901603 T2 9822430 A1 9822433 A1	04-10-2001 10-06-1998 25-01-2001 10-06-1998 25-01-2000 25-01-2000 08-12-1999 15-12-1999 27-10-1999 06-10-1999 28-05-2000 17-04-2001 21-07-1999 19-07-1999 30-03-2001 25-05-2001 28-02-2000 21-07-1999 21-02-2000 28-05-1998 28-05-1998